<DOC>
	<DOC>NCT00096837</DOC>
	<brief_summary>The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.</brief_summary>
	<brief_title>A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>Relapsed or Refractory Multiple Myeloma ≥ 18 years old Able to provide consent for participation ECOG status 02 Lab values: ANC ≥ 1,000/µL WBC count ≥ 2.0/µL Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 50,000/µL AST and ALT ≤ 2 x ULN Total Bilirubin ≤ 2 x ULN Creatinine ≤ 2.0 mg/dL and Not pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>